The global critical care diagnostics market size is expected to reach USD 2.10 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 6.11% from 2025 to 2030. The key factors supporting the industry’s growth comprise the rapid awareness and acknowledgment of these tests by physicians and patients, the rise in geriatric population and chronic health conditions, the employment of telehealth services in remote areas, and technological advancements. The increased cost of the molecular diagnostics and dearth of skilled labor are factors that are expected to hinder the growth of the industry.
The critical care diagnostics market by type is categorized into routine and special chemistry, flow cytometry, hematology, immunoproteins, microbial and infectious diseases, coagulation testing, and others. The microbial and infectious diseases test diagnostics segment is projected to grow at the highest rate with a CAGR of over 7.24% during the forecast period. For example, healthcare systems spend a substantial amount of resources in the collection and processing of blood cultures for the identification of pathogens.
Critical care diagnostic tests, such as the nucleic acid amplification test, allow clinicians to detect and identify organisms more rapidly and accurately and provide guidance to clinicians, who aspire to commence the appropriate antimicrobial therapy as fast as possible and terminate the use of avoidable drugs. The critical care diagnostic market by the end-user is categorized into operation rooms, emergency rooms, and ICU’s. The emergency rooms segment in the industry is anticipated to witness the highest growth rate during the forecast period.
Request a free sample copy or view report summary: Critical Care Diagnostics Market Report
The Asia Pacific region is expected to grow at the fastest CAGR of 8.0% during the forecast period. The large presence of geriatric population, increasing prevalence of chronic diseases, increase in the number of specialty hospitals in the Asia Pacific region, and improving healthcare services and infrastructures in rural areas are the factors fueling the market growth.
The immunoproteins diagnostic test segment is estimated to account for the largest share of the critical care diagnostic market by type. The rise in demand for rapid and accurate preventive healthcare services is one of the major factors driving this market growth.
On the basis of end-users, approximately 20% of acute-care patients get admitted into ICU’s, whereas nearly 58% get admitted into emergency rooms. The emergency rooms are expected to witness exponential growth with the highest CAGR during the forecast period. The recent rise in the patient demand for ER services is due to its ability to provide initial acute care diagnosis and treatment of critically ill patients.
Grand View Research has segmented the global critical care diagnostics market report based on type, end-use, and region:
Critical Care Diagnostics Type Outlook (Revenue, USD Million, 2018 - 2030)
Routine & Special Chemistry
Flow Cytometry
Hematology
Immunoproteins
Microbial & Infectious Disease
Coagulation Testing
Others
Critical Care Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)
Operation Room
Intensive Care Unit
Emergency Rooms
Others
Critical Care Diagnostics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in Critical Care Diagnostics Market
Abbott
Danaher
F. Hoffmann-La Roche Ltd
BD
EKF Diagnostics
bioMérieux, Inc.
Siemens Healthcare Private Limited
Chembio Diagnostics, Inc.
Bayer AG
"The quality of research they have done for us has been excellent..."